This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Proton pump inhibitors (PPIs) and hearing loss

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Since the introduction of omeprazole in 1989, proton pump inhibitors (PPIs) have steadily become the mainstay in treatment of acid-related disorders (1)

  • Pavaci et al undertook an analysis of the audiological characteristics and comorbidity in patients with chronic tinnitus and found that:
    • proton pump inhibitors and levothyroxine showed a statistically significant correlation with the presence of chronic tinnitus (2)

  • Yee et al undertook a study aimed to investigate the association between proton pump inhibitor (PPI) use and risk of sensorineural hearing loss (SNHL) or tinnitus in patients with type 2 diabetes using hospital- and population-based data
    • (n=1,379) found proton pump inhibitor (PPI) use was associated with increased risk of sensorineural hearing loss (SNHL) or tinnitus (OR: 1.61, 95% CI: 1.30-1.99) with higher risk for current or recent use of PPI and high average daily dose


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page